Research Society for the Study of Diabetes in India (RSSDI), Bengaluru and Ranbaxy Laboratories Limited have teamed up with doctors to form a blue circle, the universal symbol of diabetes, at the 42nd Annual Conclave organised by the Karnataka Chapter of RSSDI from November 21-23, 2014, Bengaluru.
Doctors at the conclave on diabetes were invited to hold each other’s hand and stand around the blue circle in concentric circles. For every doctor who formed the circle, RSSDI and Ranbaxy decided to adopt a juvenile diabetes patient for his/her insulin requirements for full one year.
According to Dr K R Narasimha Shetty, Director, Karnataka Institute of Diabetology and Chairman, Organising committee, over 6,000 doctor-delegates coming from different parts of India have deliberated on various aspects of diabetes with focus on multiple organ morbidity. Major purpose of the conclave is to evaluate the factors responsible for the increasing trend of Type-2 diabetes that is being seen in India among the youth and children, and discuss the role of diabetes in cardiac dysfunction.
At the RSSDI conclave, Ranbaxy launched its medical collaboration portal and gave a demonstration of Google Glass and how it can be of great help to the healthcare fraternity. The doctors were made better aware of apps and utilities such as video recording, taking photographs through glass, searching at google platform and interactive maps. Information was provided about value-added services of Ranbaxy such as Dial a diet / Dial a Sample, Medical and apps such as Fit heart and My Steps APP.
“There are approximately 70,000 patients with Type 1 juvenile diabetes in India. Our intention behind forming the blue circle is to create awareness about the rising menace of juvenile diabetes. said Rajeev Sibal, Vice President and Head, India region, Ranbaxy.
The effort will go a long way in spreading awareness about diabetes in the country and make a difference to my patients and other people suffering from this disease, said Dr. M R Mohan, Specialty Consultant, Karnataka Institute of Diabetology and Secretary of the Organising committee,
This year, the American Diabetes Association (ADA) released a position statement which suggests new glycemic control target in children of HbA1c of less than 7.5 per cent across all pediatric age groups, replacing earlier guidelines that specified different glycemic control targets by age. Also, it is now recommended that the care of a child or adolescent with type 1 diabetes should be provided by a multidisciplinary team of specialists trained in paediatric diabetes management.